Xiamen Municipal People’s Government

Biological Medicine and Health Industry

I.Development Basis

Xiamen is the regional cluster pilot city of national strategic emerging industries in biological medicine field. It realized output value of RMB 58.9 billion in 2018, with 241 national hi-tech enterprises. The industry has covered several segments as biological product, biological food, medical equipment and diagnosis reagent, chemicals, functional healthcare food, etc. Xiamen owns the world's first hepatitis E vaccine, the first domestic pegylated interferon "Peginterferon", the world's third/China's first bivalent cervical cancer vaccine, the world's first nerve growth factor formally used for clinic purpose, China's first multiple cancer gene mutation combined test kit, and Xiamen is the world's largest coenzyme Q10 production supplier as well. The representative enterprises include Sinobioway Medicine, Amoytop Biotech, Innovax Biotech, InTec Products, Triplex International Bioscience, Kingdomway, AmoyDX, Double Medical, LP Pharma, OGAWA, surgaid Medical, etc.

II.Development Emphasis

1.R&D and industrialization of biological products, traditional Chinese medicine and natural medicine, functional foods and formula food for special medical purposes, biological therapy cutting-edge technology R&D and application.
2.R&D and industrialization of medical equipment, wearable medical health equipment.
3.Biotech services and professional technical services.
4.Professional technical services on establishment, maintenance and mining of biological information system and database.
5.Medical e-commerce services as medical e-commerce platform, logistics distribution center, etc.

III.Preferential Policy

Implementation Opinions of Xiamen for Promoting Development of Biological Medicine and Health Industry (Xia Fu Ban [2017] No.209)
Several Measures of Xiamen for Accelerating Development of Biological Medicine and Health Industry (Xia Fu Ban [2018] No.45)
Fund Supporting Measures of Haicang District for Further Promoting Development of Biological Medicine and Health Industry (Xia Hai Zheng [2016] No.200)

IV.Park Carrier

Xiamen Biobay


From:www.investxiamen.org.cn